Clinical Trial Update: TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating TNT with FLOT chemotherapy and durvalumab, followed by postoperative durvalumab, for resectable esophagogastric adenoca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• DOCETAXEL (DOCETAXEL)
• Durvalumab (durvalumab)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Esophagogastric Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING